Curcumin induces apoptosis via simultaneously targeting AKT/mTOR and RAF/MEK/ERK survival signaling pathways in human leukemia THP-1 cells

Pharmazie

Volumn 69, Issue 3, 2014, Pages 229-233

  Guo, Yong ^a   Shan, Qingqing ^a   Gong, Yuping ^a   Lin, Juan ^a   Shi, Fangfang ^a   Shi, Rui ^a   Yang, Xi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAF PROTEIN;

ACUTE MONOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MICROSCOPY; MTT ASSAY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORING AGENTS; CURCUMIN; ENZYME ACTIVATION; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; ONCOGENE PROTEIN V-AKT; RAF KINASES; TETRAZOLIUM SALTS; THIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84897130542     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3793     Document Type: Article

References (26)

1. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30: 85-94.
2. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB (2008) Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267: 133-164.
3. Beevers CS, Li F, Liu L, Huang S (2006) Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119: 757-764. (Pubitemid 44051438)
4. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-5435.
5. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH (2008) Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 259: 111-118. (Pubitemid 350235095)
6. De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F, Salles JP, Demur C, Allouche M, Payrastre B, Manenti S, Ysebaert L (2006) A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113-3122. (Pubitemid 43881553)
7. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499.
8. Gilliland DG (2004) Targeted therapies in myeloid leukemias. Ann Hematol 83 (Suppl 1): S75-76.
9. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2307.
10. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310. (Pubitemid 37328783)
11. Kornblau SM, Womble M, Qiu YH Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108: 2358-2365. (Pubitemid 44497520)
12. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199-225.
13. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10.
14. Lev-Ari S, Starr A, Vexler A, Karaush V, Loew V, Greif J, Fenig E, Aderka D, Ben-Yosef R (2006) Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res 26: 4423-4430. (Pubitemid 46031517)
15. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R (2009) Potent growth suppressive activity of curcumin in human breast cancer cells:Modulation of Wnt/beta-catenin signaling. Chem Biol Interact 181: 263-271.
16. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ (2008A) phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14: 2756-2762.
17. Rowe JM (2008) Why is clinical progress in acute myelogenous leukemia so slow? Best Pract Res Clin Haematol 21: 1-3.
18. Shishodia S, Amin HM, Lai R, Aggarwal BB (2005) Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70: 700-713. (Pubitemid 41058705)
19. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22: 686-707. (Pubitemid 351565618)
20. Steffen B, Müller-Tidow C, Schwäble J, Berdel WE, Serve H (2005) The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol 56: 195-221. (Pubitemid 41565550)
21. Talapatra S, Thompson CB (2001) Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 298:873-878. (Pubitemid 32761898)
22. Teachey DT, Grupp SA, Brown VI (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 145: 569-580.
23. Valencia A, Román-Gómez J, Cervera J, Such E, Barragán E, Bolufer P, Moscardó F, Sanz GF, Sanz MA (2009) Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 23: 1658-1666.
24. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH (2006) Notch-1 downregulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106: 2503-2513. (Pubitemid 43787677)
25. Yang CW, Chang CL, Lee HC, Chi CW, Pan JP, Yang WC (2012) Curcumin induces the apoptosis of human monocytic leukemia THP-1 cells via the activation of JNK/ERK Pathways. BMC Complement Altern Med 12: 22.
26. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165-5173. (Pubitemid 44453345)